10555-45-0Relevant academic research and scientific papers
Nickel-Catalyzed Reversible Functional Group Metathesis between Aryl Nitriles and Aryl Thioethers
Delcaillau, Tristan,Boehm, Philip,Morandi, Bill
supporting information, p. 3723 - 3728 (2021/04/07)
We describe a new functional group metathesis between aryl nitriles and aryl thioethers. The catalytic system nickel/dcype is essential to achieve this fully reversible transformation in good to excellent yields. Furthermore, the cyanide- and thiol-free reaction shows high functional group tolerance and great efficiency for the late-stage derivatization of commercial molecules. Finally, synthetic applications demonstrate its versatility and utility in multistep synthesis.
Tetrahydroisoquinoline compounds
-
, (2021/10/13)
The present invention provides a substituted aryl compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition and containing the same as PRMT5 inhibitor.
ANTIDIABETIC TRICYCLIC COMPOUNDS
-
Page/Page column 130; 131, (2015/06/03)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
COMPOUNDS AND THEIR METHODS OF USE
-
Paragraph 0242; 0243; 0245, (2014/05/25)
Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
HETEROCYCLIC COMPOUNDS FOR INHIBITING GLUTAMINASE AND THEIR METHODS OF USE
-
Page/Page column 79, (2014/06/11)
Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF
-
Page/Page column 89-90, (2014/06/11)
Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.
COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column 106, (2014/06/11)
Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.
3-Methylenecyclobutyl, Cyclopent-3-enyl, and 3-Methylenecyclobutylmethyl Radicals; Absence of Homoallylic Conjugation
Walton, John C.
, p. 231 - 236 (2007/10/02)
The 3-methylenecyclobutyl radical and the cyclopent-3-enyl radicals show such small e.s.r. hyperfine splittings from the δ- and γ-hydrogens respectively that homoallylic conjugation can be ruled out.Semiempirical SCF-MO calculations indicated that the through-space interaction of the p-orbital at Cα with the ?-orbitals is negligible because they are >2 Angstroem apart.The 3-methylenecyclobutylmethyl radical rearranges by β-scission to give the 2-allylallyl radicals.The Arrhenius parameters of the rearrangement were determined by kinetic e.s.r. spectroscopy and by study of the reduction of 3-methylenecyclobutylmethyl bromide with tri-n-butyltin hydride.The resonance stabilisation of the rearranged radical causes no significant lowering of the activation energy for β-scission.
